T L Chen

Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer.

Marianna Zahurak, Ross C. Donehower, D A Noe et al. · Journal of Clinical Oncology · 1996 · 51 citations

Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.

Lawrence W. Anderson, T L Chen, O. Michael Colvin et al. · PubMed · 1996 · 49 citations

Thrombosis, Hypertension, Therapeutic Drug Monitoring +14

Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.

Derek Armstrong, A M Huelskamp, K Ohly et al. · Journal of Clinical Oncology · 1995 · 36 citations

Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.

Marianna Zahurak, Ross C. Donehower, D A Noe et al. · PubMed · 1998 · 14 citations

Metastatic Breast Cancer, Oncology, Sequence Dependent +10

Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.

William J. Slichenmyer, Ross C. Donehower, T L Chen et al. · PubMed · 1995 · 14 citations